Current therapies for chronic hepatitis C

Drug combination achieves sustained response in more than half of patients

Keyur Patel Dr Patel is a senior research associate, and Dr McHutchison is director, gastrointestinal and hepatology research, Duke Clinical Research Institute, division of gastroenterology, Duke University Medical Center, Durham, North Carolina.

, MD &

John G. McHutchison Dr Patel is a senior research associate, and Dr McHutchison is director, gastrointestinal and hepatology research, Duke Clinical Research Institute, division of gastroenterology, Duke University Medical Center, Durham, North Carolina.Correspondence[email protected].

, MD

PREVIEW

Chronic hepatitis C is the leading indication for liver transplantation in developed nations and will continue to pose a significant health and economic burden for the next 10 to 20 years. Fortunately, there have been considerable advances in the treatment of this disease in recent years. In this article, the authors discuss combination therapy with pegylated interferon and ribavirin and identify which patients may derive the most benefit from it.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Current therapies for chronic hepatitis C

Drug combination achieves sustained response in more than half of patients

Information for

Open access

Opportunities

Help and information

Current therapies for chronic hepatitis C

Drug combination achieves sustained response in more than half of patients

PREVIEW

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature